Jasper Therapeutics, Inc. (JSPRW)
NASDAQ: JSPRW · Real-Time Price · USD · Warrants
0.0219
0.00 (0.00%)
Apr 2, 2026, 4:00 PM EDT - Market closed

Company Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.

The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells.

It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency.

Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

Jasper Therapeutics, Inc.
Jasper Therapeutics logo
CountryUnited States
Founded2018
IndustryBiotechnology
SectorHealthcare
Employees27
CEOJeetinder Mahal

Contact Details

Address:
2200 Bridge Pkwy, Suite 102
Redwood City, California 94065
United States
Phone650 549 1400
Websitejaspertx.com

Stock Details

Ticker SymbolJSPRW
ExchangeNASDAQ
Stock TypeWarrants
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001788028
CUSIP Number471871111
ISIN NumberUS4718711116

Key Executives

NamePosition
Jeetinder Singh Mahal M.B.A.President, Chief Operating Officer, Chief Executive Officer and Director
Thomas G. WiggansExecutive Chairman
Dr. Judith Anne Shizuru M.D., Ph.D.Co-Founder, Member of Scientific Advisory Board and Director
Herbert C. Cross CPAChief Financial Officer and Corporate Secretary
Alex GrayHead of Investor Relations
Matthew FordSenior Vice President of Human Resources
Dr. Daniel C. Adelman M.D.Acting Chief Medical Officer, Member of Scientific Advisory Board and Senior Clinical Advisor
Dr. Luca Di Noto Ph.D.Senior Vice President of Technical Operations
Patricia CarlosSenior Vice President of Regulatory Affairs and Quality